555 related articles for article (PubMed ID: 17683621)
1. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome.
Chen A; Frank R; Vento S; Crosby V; Chandra M; Gauthier B; Valderrama E; Trachtman H
BMC Nephrol; 2007 Aug; 8():11. PubMed ID: 17683621
[TBL] [Abstract][Full Text] [Related]
2. Membranous nephropathy with crescents: a series of 19 cases.
Rodriguez EF; Nasr SH; Larsen CP; Sethi S; Fidler ME; Cornell LD
Am J Kidney Dis; 2014 Jul; 64(1):66-73. PubMed ID: 24709471
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
4. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy.
Aaltonen S; Honkanen E
Nephrol Dial Transplant; 2011 Sep; 26(9):2871-7. PubMed ID: 21427071
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features and expression of PLA(2)R in renal tissue with idiopathic membranous nephropathy in children].
Dong YF; Sun LW; Zhang B; Kuang XY; Niu XL; Kang YL; Hao S; Wang P; Li Z; Zhu GH; Huang WY; Wu Y
Zhonghua Er Ke Za Zhi; 2018 Mar; 56(3):206-210. PubMed ID: 29518831
[No Abstract] [Full Text] [Related]
6. [Clinicopathological feature and treatment of idiopathic membranous nephropathy in children].
Wang X; Huang JP; Zhu BZ; Yao Y; Xiao HJ
Zhonghua Er Ke Za Zhi; 2011 Apr; 49(4):311-5. PubMed ID: 21624211
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil therapy in children with idiopathic membranous nephropathy.
Bhimma R; Naicker E; Ramdial PK
Clin Nephrol; 2013 Dec; 80(6):441-8. PubMed ID: 24262490
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
Yang S; Xie L; Xue W; Yin A; Lu W
Nephrology (Carlton); 2013 Sep; 18(9):615-22. PubMed ID: 23889815
[TBL] [Abstract][Full Text] [Related]
9. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan.
Shiiki H; Saito T; Nishitani Y; Mitarai T; Yorioka N; Yoshimura A; Yokoyama H; Nishi S; Tomino Y; Kurokawa K; Sakai H;
Kidney Int; 2004 Apr; 65(4):1400-7. PubMed ID: 15086481
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
Liang Q; Li H; Xie X; Qu F; Li X; Chen J
Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
[TBL] [Abstract][Full Text] [Related]
11. Early initiation of immunosuppressive treatment in membranous nephropathy patients.
Chan CK; Lai TS; Chen PM; Chou YH; Wu CF; Chiu YL; Chiang WC; Chen YM; Chu TS; Wu KD
J Formos Med Assoc; 2017 Apr; 116(4):266-275. PubMed ID: 28202222
[TBL] [Abstract][Full Text] [Related]
12. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan.
Yamaguchi M; Ando M; Katsuno T; Tsuboi N; Maruyama S
Ren Fail; 2018 Nov; 40(1):435-441. PubMed ID: 30052488
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
Kang Z; Li Z; Duan C; Wu T; Xun M; Ding Y; Zhang Y; Zhang L; Yin Y
Pediatr Nephrol; 2015 Jul; 30(7):1121-9. PubMed ID: 25773534
[TBL] [Abstract][Full Text] [Related]
14. Overview of current and alternative therapies for idiopathic membranous nephropathy.
Tran TH; J Hughes G; Greenfeld C; Pham JT
Pharmacotherapy; 2015 Apr; 35(4):396-411. PubMed ID: 25884528
[TBL] [Abstract][Full Text] [Related]
15. Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.
Cheng P; Xie Q; Liu S; Liu X; Wang L; Hao CM
Rev Assoc Med Bras (1992); 2024; 70(4):e20230871. PubMed ID: 38716932
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
Dussol B; Morange S; Burtey S; Indreies M; Cassuto E; Mourad G; Villar E; Pouteil-Noble C; Karaaslan H; Sichez H; Lasseur C; Delmas Y; Nogier MB; Fathallah M; Loundou A; Mayor V; Berland Y
Am J Kidney Dis; 2008 Oct; 52(4):699-705. PubMed ID: 18585835
[TBL] [Abstract][Full Text] [Related]
17. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.
Hofstra JM; Wetzels JF
Nephrol Dial Transplant; 2008 Nov; 23(11):3534-8. PubMed ID: 18559961
[TBL] [Abstract][Full Text] [Related]
18. Membranous glomerulonephritis: treatment response and outcome in children.
Valentini RP; Mattoo TK; Kapur G; Imam A
Pediatr Nephrol; 2009 Feb; 24(2):301-8. PubMed ID: 18846392
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment.
Polanco N; Gutiérrez E; Rivera F; Castellanos I; Baltar J; Lorenzo D; Praga M;
Nephrol Dial Transplant; 2012 Jan; 27(1):231-4. PubMed ID: 21624942
[TBL] [Abstract][Full Text] [Related]
20. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy.
Tsuboi N; Kawamura T; Miyazaki Y; Utsunomiya Y; Hosoya T
Nephrol Dial Transplant; 2011 Nov; 26(11):3555-60. PubMed ID: 21771759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
